姓名 | 職稱 | 持有股份 | 代表法人 |
---|---|---|---|
Ye,Chui-Jing | Chairman | 1.54% | |
Yang,Wei-Fen | Director | 1.10% | |
Jiang,Wei-Feng | Director | 0.00% | |
Hong,Pei-Zhen | Director | 0.63% | ZHONG KAI INVESTMENT CO., LTD. |
Zhang,Zuo-Xia | Independent Director | 0.00% | |
Song,Si-Jun | Independent Director | 0.00% | |
Chen,Jun-Zhao | Independent Director | 0.00% |
項目 | 2025 | 2024 | 2023 |
---|---|---|---|
Operating income | 1,681,537 | 7,264,439 | 7,629,550 |
Operating cost | 1,455,925 | 5,960,195 | 6,433,353 |
Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
Operating gross profit (loss) | 225,612 | 1,304,244 | 1,196,197 |
Unrealized profit (loss) on sales of goods | - | - | - |
Realized profit (loss) on sales of goods | - | - | - |
Operating gross profit (loss), net | 225,612 | 1,304,244 | 1,196,197 |
Operating expenses | 220,003 | 1,479,338 | 1,569,489 |
Other gain (loss), net | - | - | - |
Operating profit (loss) | 5,609 | -175,094 | -373,292 |
Non-operating income and expenses | -3,760 | 490,118 | 227,258 |
Net profit (loss) before tax | 1,849 | 315,024 | -146,034 |
Income tax expense (benefits) | 19,547 | 108,883 | 232,583 |
Net profit (loss) of ongoing business for the current period | -17,698 | 206,141 | -378,617 |
Profit (loss) of closed units | - | - | - |
Profit (loss) of non-jointly controlled equity before merger | - | - | - |
Net profit (loss) for the current period | -17,698 | 206,141 | -378,617 |
Other comprehensive profit (loss), net | 93,762 | 256,512 | 69,242 |
Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
Total comprehensive profit and loss for the current period | 76,064 | 462,653 | -309,375 |
Net profit (loss) attributable to owners of parent company | 6,191 | 46,748 | -303,314 |
Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
Net profit (loss) attributable to non-controlling interests | -23,889 | 159,393 | -75,303 |
Comprehensive profit (loss) attributable to owners of parent company | 34,699 | 144,432 | -346,570 |
Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
Comprehensive profit (loss) attributable to non-controlling interests | 41,365 | 318,221 | 37,195 |
Basic earnings per share (yuan) | 0 | 0 | 0 |
項目 | 2025 | 2024 | 2023 |
---|---|---|---|
Net cash inflow (outflow) from operating activities | -502,252 | 869,620 | 1,057,890 |
Net cash inflows (outflows) from investing activities | -429,091 | -2,504,586 | -235,505 |
Net cash inflow (outflow) from financing activities | 539,799 | 768,309 | -432,340 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 80,728 | 242,259 | 129,261 |
Increase (decrease) in cash and cash equivalents in the current period | -310,816 | -624,398 | 519,306 |
Beginning balance of cash and cash equivalents | 3,972,713 | 4,597,111 | 4,077,805 |
Ending balance of cash and cash equivalents | 3,661,897 | 3,972,713 | 4,597,111 |
項目 | 2025 | 2024 | 2023 |
---|---|---|---|
Current asset | 7,817,491 | 7,921,373 | 8,726,100 |
Non-current asset | 9,400,353 | 9,122,035 | 10,143,738 |
Total asset | 17,217,844 | 17,043,408 | 18,869,838 |
Current liability | 4,169,610 | 4,167,470 | 3,686,254 |
Non-current liability | 3,341,630 | 3,228,974 | 4,965,281 |
Total liability | 7,511,240 | 7,396,444 | 8,651,535 |
share capital | 6,936,797 | 6,936,797 | 6,936,797 |
Equity - secruity token | - | - | - |
capital reserve | 1,321,929 | 1,322,901 | 1,233,814 |
retained earning | -1,780,334 | -1,780,493 | -1,867,974 |
Other equity | -756,604 | -791,144 | -848,095 |
Treasury stock | - | - | - |
Total equity attributable to owners of parent company | 5,721,788 | 5,688,061 | 5,454,542 |
Equity attributable to former owner of business combination under common control | - | - | - |
Equity attributable to non-controlling interest before business merger under common control | - | - | - |
Non-controlling interests | 3,984,816 | 3,958,903 | 4,763,761 |
Total Equity | 9,706,604 | 9,646,964 | 10,218,303 |
Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
Net asset value per share | 8 | 8 | 7 |
標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
---|---|---|---|---|
委外雛型晶片模具製作一個 | 國立臺灣大學醫學院附設醫院 | 103/06/27 | 587643.0 | 是 |
隔熱元件量測設備 | 行政院原子能委員會核能研究所 | 102/08/27 | 否 |
日期 | 違反法規法條 | 罰鍰金額 |
---|---|---|
2023/12/08 | Paragraph 1, Article 6 of the Occupational Safety and Health Act | |
2022/08/08 | Paragraph 3, Article 12 of the Occupational Safety and Health Act | |
2018/05/24 | Paragraph 1, Article 10 of the Occupational Safety and Health Act | |
2018/03/02 | Paragraph 1, Article 27 of the Occupational Safety and Health Act |